In two retrospective case–control studies, involving a group of 368 patients with deep-vein thrombosis vs. 395 non-thrombotic patients [14] and a group of 118 patients with SSNHL vs. 352 healthy subjects [18], respectively, the prothrombin G20210A mutation was considered a strong independent risk factor for SSNHL (p < 0.0001 and p = 0.0091, respectively). This evidence concerns the gene F2 and deep vein thrombosis.